Old world leishmaniasis: An emerging infection among deployed US military and civilian workers

Clinical Infectious Diseases

Volumn 39, Issue 11, 2004, Pages 1674-1680

  Weina, Peter J ^a   Neafie, Ronald C ^c   Wortmann, Glenn ^d   Polhemus, Mark ^d   Aronson, Naomi E ^b,d,e  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e National Foundation for Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; IMIDAZOLE DERIVATIVE; IMIQUIMOD; INSECT REPELLENT; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE; N ACETYL S NITROSOPENICILLAMINE; PARAFFIN; PAROMOMYCIN; PERMETHRIN; STIBOGLUCONATE SODIUM; UREA;

AMASTIGOTE; ARTHRALGIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CRYOTHERAPY; CULTURE MEDIUM; DESQUAMATION; EPIDEMIC; FATIGUE; FOLLOW UP; HEADACHE; HUMAN; HYPERTHERMIC THERAPY; INSECT BITE; IRAQ; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIA TROPICA; LIVER TOXICITY; MYALGIA; PANCREATITIS; PAPULE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUNCH BIOPSY; RASH; REVIEW; SKIN LEISHMANIASIS; SKIN ULCER; SOLDIER; UNITED STATES; VIRUS REACTIVATION; VISCERAL LEISHMANIASIS;

HUMANS; IRAQ; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MILITARY PERSONNEL; UNITED STATES; WAR;

EID: 9644274095     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/425747     Document Type: Review

References (39)

1. Centers for Disease Control and Prevention. Update: cutaneous leishmaniasis in US military personnel-southwest/central Asia, 2002-2004. MMWR Morb Mortal Wkly Rep 2004; 53:264-5.
2. Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol 1996; 14:425-31.
3. Gillis D, Klaus S, Schnur LF, et al. Diffusely disseminated cutaneous Leishmania major infection in a child with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1995; 14:247-9.
4. Centers for Disease Control and Prevention. Cutaneous leishmaniasis in US military personnel -southwest/central Asia. MMWR Morb Mortal Wkly Rep 2003; 52:1009-12.
5. Rahim GF, Tatar IH. Oriental sore in Iraq. Bull Endem Dis (Baghdad) 1966; 8:29-54.
6. Wortmann G, Sweeney C, Houng HS, et al. Rapid diagnosis of leishmaniasis by fluorogenic polymerase chain reaction. Am J Trop Med Hyg 2001; 65:583-7.
7. Magill AJ, Grogl M, Gasser RA Jr, Sun W, Oster CN. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993; 328:1383-7.
8. Currie M. Treatment of cutaneous leishmaniasis by curettage. Br Med J (Clin Res Ed) 1983; 287:1105-6.
9. Bassiouny A, El Meshad M, Talaat M, Kutty K, Metawaa B. Cryosurgery in cutaneous leishmaniasis. Br J Dermatol 1982; 107:467-74.
10. Uzun S, Uslular C, Yucel A, Acar M, Ozpoyraz M, Memisoglu H. Cutaneous leishmaniasis: evaluation of 3074 cases in the Cukurova region of Turkey. Br J Derm 1999; 140:347-50.
11. Memisoglu H, Kotogyan A, Acar M, Ozpoyraz M, Uzun S. Cryotherapy in cases with leishmaniasis cutis. J Eur Acad Dermatol Venereol 1995; 4:9-13.
12. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43:281-3.
13. Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 1990; 42:43-50.
14. Reithinger R, Mohsen M, Kolaczinski J, Davies CR, David JR. A randomized controlled trial to test the efficacy of thermotherapy against Leishmania tropica in Kabul, Afghanistan [abstract 776]. In: 52nd Annual Meeting of the American Society for Tropical Medicine and Hygiene (Philadelphia). Northbrook, IL: American Society for Tropical Medicine and Hygiene, 2003:548.
15. Lopez-Jaramillo P, Ruano C, Rivera J, et al. Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet 1998; 351:1176-7.
16. Davidson RN, Yardley V, Croft SL, Konecny P, Benjamin N. A topical nitric oxide-generating therapy for cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94:319-22.
17. el-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 1992; 27:227-31.
18. Ben Salah A, Zakraoui H, Zaatour A, et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995; 53:162-6.
19. Asilian A, Jalayer T, Nilforooshzadeh M, et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: doubleblind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ 2003; 81:353-9.
20. Faghihi G, Tavakoli-kia R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol 2003; 28:13-6.
21. Singh S, Singh R, Sundar S. Failure of ketoconazole treatment in cutaneous leishmaniasis. Int J Derm 1995; 34:120-1.
22. Berman JD. Activity of imidazoles against Leishmania tropica in human macrophage cultures. Am J Trop Med Hyg 1981; 30:566-9.
23. Momeni AZ, Jalayer T, Emamjomeh M, et al. Treatment of cutaneous leishmaniasis with itraconazole: randomized double-blind study. Arch Dermatol 1996; 132:784-6.
24. Salmanpour R, Handjani F, Nouhpisheh MK. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. J Dermatolog Treat 2001; 12:159-62.
25. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891-5.
26. Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38:1266-72.
27. Wortmann G, Fraser S, Aronson N, et al. Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis. Clin Infect Dis 1998; 26:1006-7.
28. Belazzoug S, Neal RA. Failure of meglumine antimoniate to cure cutaneous lesions due to Leishmania major in Algeria. Trans R Soc Trop Med Hyg 1986; 80:670-1.
29. Momeni AZ, Reiszadae MR, Aminjavaheri M. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate. Int J Dermatol 2002; 41:441-3.
30. Aronson NE, Wortmann GW, Johnson SC, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent US military experience. Clin Infect Dis 1998; 27:1457-64.
31. Wortmann GW, Aronson NE, Miller RS, Blazes D, Oster CN. Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis 2000; 31:199-201.
32. World Health Organization. Communicable Disease Surveillance and Report. 19 March 2003. http://www.who.int/emc/diseases/leish/index.html. Accessed 3 November 2004
33. le Fichoux Y, Quaranta JF, Aufeuvre JP, et al. Occurrence of Leishmania infantum parasiternia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol 1999; 37:1953-7.
34. American Red Cross. Blood donation eligibility guidelines. 14 September 2004. http://www.redcross.org/services/biomed/0,1082,0_557_,00.html#infec. Accessed 3 November 2004.
35. Centers for Disease Control and Prevention. Two cases of visceral leishmaniasis in US military personnel-Afghanistan, 2002-2004. MMWR Morb Mortal Wkly Rep 2004; 53:265-7.
36. Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol 2002; 9:951-8.
37. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6:849-54.
38. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341:1795-800.
39. Guerin P, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002; 2:494-501.